Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer
(2018)
Journal Article
Alfarsi, L. H., Elansari, R., Toss, M. S., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., …Green, A. R. (2018). Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. Breast Cancer Research and Treatment, https://doi.org/10.1007/s10549-018-4978-5
PURPOSE: Identification of effective and reliable biomarkers that could be used to predict the efficacy of endocrine therapy is of crucial importance to the management of oestrogen receptor positive (ER+) breast cancer (BC). KIF18A, a key regulator o... Read More about Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.